⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,852
Total Claims
$6.1M
Drug Cost
1,059
Beneficiaries
$5,736
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+46%
Cost per patient vs peers
$5,736 vs $3,933 avg
-1%
Brand preference vs peers
50.7% vs 51.2% avg
Brand vs Generic
49% generic
Brand: 4,311 claims · $5.8M
Generic: 4,192 claims · $156K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 341 | $679K |
| Dulaglutide | 329 | $661K |
| Tirzepatide | 242 | $432K |
| Empagliflozin | 280 | $425K |
| Insulin Glargine,hum.Rec.Anlog | 294 | $363K |
| Insulin Degludec | 160 | $354K |
| Dapagliflozin Propanediol | 211 | $282K |
| Empagliflozin/Metformin Hcl | 173 | $232K |
| Insulin Lispro | 113 | $206K |
| Insulin Aspart | 105 | $191K |
| Insulin Regular, Human | 39 | $150K |
| Insulin Degludec | 98 | $141K |
| Semaglutide | 67 | $137K |
| Sitagliptin Phosphate | 94 | $129K |
| Empagliflozin/Metformin Hcl | 91 | $104K |
Prescribing Profile
Patient Profile
68
Avg Age
70%
Female
2.12
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About